Sysmex (OTCMKTS:SSMXY) Rating Lowered to Strong Sell at Zacks Research

Sysmex (OTCMKTS:SSMXY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Sysmex Stock Down 1.9%

Shares of SSMXY stock opened at $9.43 on Tuesday. The company has a market capitalization of $5.94 billion, a price-to-earnings ratio of 24.82 and a beta of 1.07. Sysmex has a one year low of $8.01 and a one year high of $18.10. The company’s fifty day moving average price is $8.91 and its 200-day moving average price is $9.07. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The firm had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Sell-side analysts expect that Sysmex will post 0.42 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.